Nanjing Hicin Pharmaceutical Co., Ltd. Announces Earnings Results for the First Quarter Ended March 31, 2021
April 07, 2021 at 01:08 pm
Share
Nanjing Hicin Pharmaceutical Co., Ltd. announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced sales was CNY 162.203 million compared to CNY 166.174 million a year ago. Operating income was CNY 14.719 million compared to CNY 19.877 million a year ago. Net income was CNY 13.509 million compared to CNY 17.167 million a year ago. Basic earnings per share from continuing operations was CNY 0.1126 compared to CNY 0.1431 a year ago.
Nanjing Hicin Pharmaceutical Co Ltd is a pharmaceutical company engaged in research, development and production of chemical preparations, active pharmaceutical ingredients and intermediates. The Company's primary products are torsemide for injection, tigecycline for injection, cefoxitin sodium for injection, cefotiam for injection and omeprazole sodium for injection. The torsemide for injection is a loop diuretic. The tigecycline for injection is an intravenous administrated glycyrrhizin antibiotic for the treatment of complex skin and skin structure infections or complex intra-abdominal infections. The cefoxitin sodium for injection is a cephalosporin antibiotic used for the treatment of respiratory, urinary and gastrointestinal infections. Its products cover a range of therapeutic areas, including diuresis, cardiovascular, anti-infection, digestive system, immune regulation, hypoglycemic and orthopedics.
NANJING HICIN PHARMACEUTICAL CO., LTD. 
